JP7348171B2 - 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 - Google Patents

子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 Download PDF

Info

Publication number
JP7348171B2
JP7348171B2 JP2020516959A JP2020516959A JP7348171B2 JP 7348171 B2 JP7348171 B2 JP 7348171B2 JP 2020516959 A JP2020516959 A JP 2020516959A JP 2020516959 A JP2020516959 A JP 2020516959A JP 7348171 B2 JP7348171 B2 JP 7348171B2
Authority
JP
Japan
Prior art keywords
day
patient
administered
weeks
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522571A (ja
JP2020522571A5 (cg-RX-API-DMAC7.html
Inventor
ロウマイェ、アーネスト
ゴットランド、ジャン－ピエール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of JP2020522571A publication Critical patent/JP2020522571A/ja
Publication of JP2020522571A5 publication Critical patent/JP2020522571A5/ja
Priority to JP2023084336A priority Critical patent/JP7657855B2/ja
Application granted granted Critical
Publication of JP7348171B2 publication Critical patent/JP7348171B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020516959A 2017-06-05 2018-06-05 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 Active JP7348171B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023084336A JP7657855B2 (ja) 2017-06-05 2023-05-23 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515268P 2017-06-05 2017-06-05
US62/515,268 2017-06-05
PCT/EP2018/064768 WO2018224498A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023084336A Division JP7657855B2 (ja) 2017-06-05 2023-05-23 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画

Publications (3)

Publication Number Publication Date
JP2020522571A JP2020522571A (ja) 2020-07-30
JP2020522571A5 JP2020522571A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7348171B2 true JP7348171B2 (ja) 2023-09-20

Family

ID=62620835

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020516959A Active JP7348171B2 (ja) 2017-06-05 2018-06-05 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画
JP2023084336A Active JP7657855B2 (ja) 2017-06-05 2023-05-23 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023084336A Active JP7657855B2 (ja) 2017-06-05 2023-05-23 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画

Country Status (12)

Country Link
US (2) US11980621B2 (cg-RX-API-DMAC7.html)
EP (1) EP3634418A1 (cg-RX-API-DMAC7.html)
JP (2) JP7348171B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250117836A (cg-RX-API-DMAC7.html)
CN (1) CN110996956A (cg-RX-API-DMAC7.html)
AU (2) AU2018280742B2 (cg-RX-API-DMAC7.html)
CA (1) CA3066190A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992612A1 (cg-RX-API-DMAC7.html)
MA (1) MA49256A (cg-RX-API-DMAC7.html)
MX (1) MX2019014483A (cg-RX-API-DMAC7.html)
SG (1) SG11201911598WA (cg-RX-API-DMAC7.html)
WO (1) WO2018224498A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3518933T4 (da) 2016-09-30 2025-04-22 Takeda Pharmaceuticals Co Fremgangsmåder til behandling af uterusfibromer og endometriose
MX2019014482A (es) 2017-06-05 2020-08-17 ObsEva SA Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación.
KR20250117836A (ko) 2017-06-05 2025-08-05 깃세이 야쿠힌 고교 가부시키가이샤 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
EP3873465B1 (en) 2018-10-29 2025-01-15 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
US20220305017A1 (en) * 2019-08-08 2022-09-29 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
WO2022101303A1 (en) * 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
TWI796144B (zh) * 2021-02-23 2023-03-11 大陸商南京明德新藥研發有限公司 噻吩並嘧啶二酮類化合物及其應用
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014042176A1 (ja) 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
JP2016513708A (ja) 2013-03-15 2016-05-16 アッヴィ・インコーポレイテッド 月経出血過多および子宮類線維腫の処置に使用するための組成物
WO2018030317A1 (ja) 2016-08-08 2018-02-15 キッセイ薬品工業株式会社 子宮内膜症治療剤の用法・用量

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342760A (en) 1992-06-10 1994-08-30 Abbott Laboratories Determination of estradiol by competitive immunoassay
US5663054A (en) 1995-03-03 1997-09-02 Abbott Laboratories Determination of steroids by competitive immunoassay
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
EP1300398B1 (en) 2000-07-05 2006-04-05 Astellas Pharma Inc. Propane-1,3-dione derivatives
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
ATE407679T1 (de) 2003-07-07 2008-09-15 Neurocrine Biosciences Inc Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
BRPI0609625A2 (pt) 2005-03-31 2010-04-20 Astellas Pharma Inc derivados de propano-1,3-diona ou sal destes
BRPI0617436B8 (pt) 2005-10-19 2021-05-25 Kissei Pharmaceutical derivado heterocíclico fundido, composição farmacêutica compreendendo o mesmo e usos do dito derivado na prevenção ou tratamento de doença dependente de hormônio sexual e na regulação da reprodução, contracepção ou indução de ovulação
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
BR112012020110B1 (pt) 2010-02-10 2021-06-08 Kissei Pharmaceutical Co., Ltd. composto derivado heterocíclico fusionado, composição farmacêutica que compreende o mesmo e uso terapêutico do dito composto
HK1199878A1 (en) 2012-01-16 2015-07-24 Bayer Intellectual Property Gmbh Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists
EP2817621A4 (en) 2012-02-21 2016-02-24 Univ Northwestern PROOF OF ANTI-MÜLLER-HORMON IN FULL BLOOD
CN104603114B (zh) 2012-09-07 2017-06-20 安斯泰来制药株式会社 磺酰脒化合物的制造方法
LT3415517T (lt) 2012-09-28 2022-06-10 Takeda Pharmaceutical Company Limited Kristalinė 1-(4-(1-(2,6-difluorbenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)-2,4-diokso-1,2,3,4- tetrahidrotieno(2,3-d)pirimidin-6-il)fenil)-3-metoksikarbamido forma
AR095785A1 (es) 2013-04-09 2015-11-11 Bayer Pharma AG Derivados de espiroindolina y composiciones farmacéutica de los mismos
WO2017040841A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
DK3518933T4 (da) 2016-09-30 2025-04-22 Takeda Pharmaceuticals Co Fremgangsmåder til behandling af uterusfibromer og endometriose
KR20250117836A (ko) 2017-06-05 2025-08-05 깃세이 야쿠힌 고교 가부시키가이샤 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
MX2019014482A (es) 2017-06-05 2020-08-17 ObsEva SA Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación.
EP3876943A2 (en) 2018-11-07 2021-09-15 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014042176A1 (ja) 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
JP2016513708A (ja) 2013-03-15 2016-05-16 アッヴィ・インコーポレイテッド 月経出血過多および子宮類線維腫の処置に使用するための組成物
WO2018030317A1 (ja) 2016-08-08 2018-02-15 キッセイ薬品工業株式会社 子宮内膜症治療剤の用法・用量

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fertility and Sterility，2017年03月，107(3)，568-570
K MACKAY，ObsEva SA [Online]，2017年02月21日，[令和４年６月８日検索]，https://research-doc.credit-suisse.com/docView?language=ENG&format=PDF&sourceid=csplusresearchcp&document_id=1071589801&serialid=CA9%2FwyYuDFgDNmTH8nNYP3iUspTz8%2ByPI4mTQ%2F76dNE%3D&cspId=null

Also Published As

Publication number Publication date
US20240293414A1 (en) 2024-09-05
JP2020522571A (ja) 2020-07-30
KR20200027481A (ko) 2020-03-12
JP7657855B2 (ja) 2025-04-07
CA3066190A1 (en) 2018-12-13
EA201992612A1 (ru) 2020-05-20
AU2018280742B2 (en) 2023-12-21
KR20250117836A (ko) 2025-08-05
EP3634418A1 (en) 2020-04-15
AU2024201701A1 (en) 2024-04-04
CN110996956A (zh) 2020-04-10
MX2019014483A (es) 2020-08-17
KR102839190B1 (ko) 2025-07-28
SG11201911598WA (en) 2020-01-30
AU2024201701B2 (en) 2025-04-10
WO2018224498A1 (en) 2018-12-13
US11980621B2 (en) 2024-05-14
US20200138819A1 (en) 2020-05-07
JP2023113715A (ja) 2023-08-16
AU2018280742A1 (en) 2020-01-30
MA49256A (fr) 2021-05-26

Similar Documents

Publication Publication Date Title
JP7348171B2 (ja) 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画
JP7485815B2 (ja) 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画
JP2001302547A (ja) 女性の性機能不全を処置するための組成物および方法
KR20210100623A (ko) 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법
AU2020325721A1 (en) GnRH antagonists for the treatment of estrogen-dependent disorders
KR20220061120A (ko) 에스트로겐-의존성 장애 치료용 조성물 및 방법
EP3873465B1 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
EA044130B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
EA049129B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери
HK40059353B (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40059353A (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220912

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20230224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230907

R150 Certificate of patent or registration of utility model

Ref document number: 7348171

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150